AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Relmada Therapeutics, Inc.
Video analysis: RLMD
All videosNo video analysis for this stock yet. Request one from our team.
News: RLMD
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026.
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Relmada Therapeutics Q2 Earnings Call Highlights
Relmada Therapeutics NASDAQ: RLMD said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026.
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript
Critical Review: Relmada Therapeutics (NASDAQ:RLMD) versus Novo Nordisk A/S (NYSE:NVO)
Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Novo Nordisk A/S (NYSE: NVO - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership. Volatility and Risk Relmada Therapeutics has a
